SCHEMBL3256147

SCHEMBL3256147

CCCc1ccc(S(=O)(=O)Nc2ncc(CC(=O)N3CCOCC3)s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
ALDH1A1 P00352 4/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52
HSD11B1 P28845 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.42
AKT1 P31749 1/20 0.42
IRS1 P35568 1/20 0.42
GAB1 Q13480 1/20 0.42
MAPT P10636 1/20 0.41
NAMPT P43490 1/20 0.41
HPGD P15428 1/20 0.41
PABPC1 P11940 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248063 0.91 HPGD (0.51) TSHRALDH1A1MAPK1KMT2AHSD11B1
SCHEMBL3251304 0.90 HSD11B1 (0.49) TSHRALDH1A1MAPK1KMT2AHSD11B1
SCHEMBL3253323 0.89 HSD11B1 (0.50) TSHRALDH1A1MAPK1KMT2AHSD11B1
SCHEMBL3253320 0.89 HSD11B1 (0.50) TSHRALDH1A1MAPK1KMT2AHSD11B1
SCHEMBL5831641 0.85 AKT1 (0.58) TSHRALDH1A1MAPK1KMT2ANPSR1
SCHEMBL3254312 0.84 MAPT (0.52) ALDH1A1MAPK1KMT2AHSD11B1LMNA
SCHEMBL5832372 0.83 TSHR (0.54) TSHRALDH1A1MAPK1KMT2AHSD11B1
SCHEMBL3253280 0.83 HSD11B1 (0.48) ALDH1A1MAPK1KMT2AHSD11B1NPSR1
SCHEMBL3255832 0.83 HSD11B1 (0.52) ALDH1A1MAPK1KMT2AHSD11B1L3MBTL1
SCHEMBL3251270 0.83 HSD11B1 (0.52) TSHRALDH1A1MAPK1KMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461325-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003043999-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US disclosed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 TSHR 1374/4885ALDH1A1 56/4885MAPK1 1460/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 TSHR 4127/4885ALDH1A1 47/4885MAPK1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.